Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies

Acta Oncol. 2016 Jul;55(7):930-2. doi: 10.3109/0284186X.2015.1120885. Epub 2016 Mar 31.

Authors

Fréderic Franconieri¹, Nicolas Martin-Silva¹, Hubert de Boysson¹, Françoise Galateau-Salle², Jean-François Emile³, Boris Bienvenu¹, Achille Aouba¹

Affiliations

¹ a Department of Internal Medicine and Clinical Immunology , CHU Côte De Nacre, Université Basse Normandie , Caen , France.
² b Department of Pathology , CHU Côte De Nacre, Université Basse Normandie , Caen , France.
³ c Department of Pathology , CHU Ambroise Paré , Boulogne , France.

PMID: 27031008
DOI: 10.3109/0284186X.2015.1120885

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Erdheim-Chester Disease / drug therapy*
Erdheim-Chester Disease / genetics
Erdheim-Chester Disease / immunology
Female
Hand-Foot Syndrome / etiology
Humans
Immunotherapy / methods
Indoles / administration & dosage*
Indoles / adverse effects
Interleukin 1 Receptor Antagonist Protein / administration & dosage*
Mutation
Proto-Oncogene Proteins B-raf / genetics
Sulfonamides / administration & dosage*
Sulfonamides / adverse effects
Vemurafenib

Substances

Indoles
Interleukin 1 Receptor Antagonist Protein
Sulfonamides
Vemurafenib
BRAF protein, human
Proto-Oncogene Proteins B-raf